SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-002636
Filing Date
2024-01-18
Accepted
2024-01-18 07:30:19
Documents
12
Period of Report
2024-01-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K ef20019054_8k.htm   iXBRL 8-K 44179
  Complete submission text file 0001140361-24-002636.txt   185024

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bbio-20240117.xsd EX-101.SCH 3869
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20240117_lab.xml EX-101.LAB 22547
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20240117_pre.xml EX-101.PRE 16047
6 EXTRACTED XBRL INSTANCE DOCUMENT ef20019054_8k_htm.xml XML 4225
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 24540121
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)